E.I. Du Pont De Nemours & Co. v. MacDermid Printing Solutions, L.L.C.

657 F. App'x 1004
CourtCourt of Appeals for the Federal Circuit
DecidedAugust 19, 2016
Docket2015-1777
StatusUnpublished

This text of 657 F. App'x 1004 (E.I. Du Pont De Nemours & Co. v. MacDermid Printing Solutions, L.L.C.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
E.I. Du Pont De Nemours & Co. v. MacDermid Printing Solutions, L.L.C., 657 F. App'x 1004 (Fed. Cir. 2016).

Opinion

Lourie, Circuit Judge.

E.I. du Pont de Nemours & Co. (“DuPont”) appeals from the decision of the United States District Court for the District of New Jersey granting summary judgment that claims 1, 6, 22, 30, 33, 36, 39-41, and 48 of U.S. Patent 6,773,859 (“the ’859 patent”) are invalid as obvious, and that claims 1, 3-4, and 7-8 of U.S. Patent 6,171,758 (“the ’758 patent”), as construed by the district court, were not infringed by MacDermid Printing Solutions, L.L.C. (“MacDermid”). See E.I. du Pont de Nemours & Co. v. MacDermid Printing Sols., L.L.C. No. 06-3383, 2014 WL 4657300 (D.N.J. Sept. 17, 2014) (“Summary' Judgment Order”); E.I. du Pont de Nemours & Co. v. MacDermid Printing Sols., L.L.C., No. 06-3383, 2010 *1006 WL 988549 (D.N.J. Mar. 15, 2010) (“Claim Construction Order*’). Because the district court did not err in granting summary judgment of invalidity of the ’859 patent or in granting summary judgment of nonin-fringement of the ’758 patent, we affirm.

BACKGROUND

A

DuPont owns the ’859 patent, directed to a process of making a flexographic printing plate used to print images on flexible materials. The ’859 patent claims priority from a provisional application filed on March 6, 2001, ’859 patent, Certificate of Corr. dated July 26, 2005; see also E.I. du Pont de Nemours & Co. v. MacDermid Printing Sols., L.L.C., 525 F.3d 1353, 1362-63 (Fed. Cir. 2008), and was considered by the district court to have a date of invention on or before June 9, 1999, Summary Judgment Order, 2014 WL 4657300, at *9.

A flexographic printing plate bearing the image to be printed is typically prepared from an “imaging” process and a “development” process. As shown below, a flexographic printing plate consists of multiple layers, including a base support layer and a photopolymerizable layer, which contains photoinitiators, monomers, and elastomeric binders. During the imaging process, selected areas of the photopolym-erizable layer are exposed to ultraviolet (“UV”) light, which causes the exposed areas to polymerize. The unpolymerized material is then removed in the development process, leaving the polymerized material on the plate, which forms the relief image to be printed.

[[Image here]]

Joint App. (“J.A.”) 3692.

As of June 1999, there existed two methods for imaging: analog and digital. Summary Judgment Order, 2014 WL 4657300, at *16. Analog imaging was first developed in the 1950s. In analog imaging, a sheet bearing a negative of the image to be printed is placed on top of the photopolym-erizable layer. A transparent coversheet is then placed over the negative. The plate is then exposed to UV light, which passes through the transparent areas of the negative and causes the exposed portions of the photopolymerizable layer to polymerize. The opaque areas of the negative block the UV light and thus prevent the photopolym- *1007 erizable layer underneath those areas from polymerizing. After the removal of the coversheet and negative, the unpolymerized portions of the photopolymerizable layer are removed in the development process, leaving only the relief image. The analog imaging process is illustrated below,

J.A. 3692-93.

In 1992, DuPont developed the digital imaging technology, in which a thin, opaque infrared ablation layer is applied over the photopolymerizable layer. That ablation layer can block UV light, but can be removed by an infrared laser. Thus, one difference between a digital plate and an analog plate is that a digital plate has an ablation layer. In digital imaging, the image to be printed is digitized and stored in a computer. The computer then guides an infrared laser to imagewise remove, or ablate, select portions of the ablation layer. That .process creates an in-situ mask directly on top of the photopolymerizable layer. The plate is then exposed to UV light, and the openings in the in-situ mask allow the UV light to pass through, such that the exposed portions of the photopo-lymerizable layer undergo polymerization. The unpolymerized material, together with the ablation layer above it, is then removed in the development process. The digital imaging process is illustrated below.

*1008 [[Image here]]

J.A. 3697-99.

The “development” process follows the “imaging” process. As of June 1999, there existed the following development techniques: solvent, water, air knife, and thermal. Summary Judgment Order, 2014 WL 4657300, at *16. According to DuPont, solvent and thermal development methods have been known since at least the 1960s. Appellant’s Br. 2. The solvent development method uses chemical solvents to wash and remove the unpolymerized portions of the photopolymerizable layer. According to DuPont, although solvent development requires the use of chemical solvents, which posed certain environmental risks, the combination of analog imaging and solvent development has been widely used for decades. Id. at 11-12. When DuPont developed digital imaging in the 1990s, it initially used the solvent method to develop the digitally imaged plates. That combination of digital imaging and solvent development is described in DuPont’s U.S. Patent 5,262,275 (“Fan”), J.A. 2421-29, which is prior art to the ’859 patent.

In contrast, the thermal development method uses heat to soften or liquefy the unpolymerized portions of the photopolym-erizable layer, and then uses absorbent material, such as paper or felt, to blot away the unpolymerized material. The pri- or art, including U.S. Patent 5,175,072 (“Martens”), J.A. 2182-99, describes the combination of analog imaging and thermal development.

*1009 DuPont’s ’859 patent claims a process for making a flexographic printing plate that combines digital imaging and thermal development techniques. Claim 30 is illustrative of the ’859 patent claims at issue in this appeal. Reproduced in independent form, claim 30 reads:

30. A process for making a flexographic printing plate comprising:
1) providing a photosensitive element comprising: at least one pho-topolymerizable layer on a support comprising an elastomeric binder, at least one monomer, and a pho-toinitiator, and at least me thermally removable layer disposed above the photopolymerizable layer, wherein the thermally removable layer is
(a) an actinic radiation opaque layer comprising (i) at least one infrared absorbing material, (ii) a radiation opaque material, wherein (i) .and (ii) can be the same or different, and at least one binder having a softening or melting temperature less than 190° C;
2) imagewise exposing the photopo-lymerizable layer to actinic radiation forming polymerized portions and unpolymerized portions; and
3) thermally treating

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Azur v. Chase Bank, USA, National Ass'n
601 F.3d 212 (Third Circuit, 2010)
Graham v. John Deere Co. of Kansas City
383 U.S. 1 (Supreme Court, 1966)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
KSR International Co. v. Teleflex Inc.
550 U.S. 398 (Supreme Court, 2007)
Dippin' Dots v. Mosey v. Esty, Jr.
476 F.3d 1337 (Federal Circuit, 2007)
Microsoft Corp. v. i4i Ltd. Partnership
131 S. Ct. 2238 (Supreme Court, 2011)
Application of Frederick C. Foster
343 F.2d 980 (Customs and Patent Appeals, 1965)
Absolute Software, Inc. v. Stealth Signal, Inc.
659 F.3d 1121 (Federal Circuit, 2011)
Shire Development, LLC v. Watson Pharmaceuticals, Inc.
787 F.3d 1359 (Federal Circuit, 2015)
Teva Pharm. United States, Inc. v. Sandoz, Inc.
135 S. Ct. 831 (Supreme Court, 2015)
Eurand, Inc. v. Mylan Pharmaceuticals Inc.
676 F.3d 1063 (Federal Circuit, 2012)
In re Ownby
471 F.2d 1233 (Customs and Patent Appeals, 1973)

Cite This Page — Counsel Stack

Bluebook (online)
657 F. App'x 1004, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ei-du-pont-de-nemours-co-v-macdermid-printing-solutions-llc-cafc-2016.